Ultrabol 150 by British Dragon

Drostanolone (Masteron) is a dihydrotestosterone derivative — it binds to aromatase and to estrogen receptors with sufficient affinity to reduce the enzyme's availability for testosterone-to-estradiol conversion and to competitively occupy receptor sites without activating them. At practical doses, Drostanolone does not fully replace AI management — an athlete running 350 mg/week of Testosterone Propionate alone typically requires consistent Anastrozole or Exemestane throughout the cycle. The same athlete running an equivalent testosterone dose as part of a Drostanolone-containing blend like Ultrabol 150 will find their bloodwork-confirmed estradiol is lower at the same AI dose, or that the same estradiol level is achieved with a reduced AI dose. The magnitude of this effect is individual and dose-dependent — athletes with high baseline aromatase activity will still require active AI; those with lower aromatization may find Drostanolone's anti-estrogenic activity sufficient to manage estrogen without pharmacological AI at standard Ultrabol 150 doses. Mid-cycle bloodwork is the only accurate tool for calibrating this individual balance.

The three components of Ultrabol 150 each produce their effects regardless of caloric approach — they respond to the athlete's nutritional environment rather than having an intrinsic directional action. In caloric surplus, Ultrabol 150 produces lean mass accumulation with minimal water retention (near zero, given Drostanolone's anti-estrogenic activity eliminating estrogenic water and Trenbolone adding no water independently). Mass gained in caloric surplus on Ultrabol 150 is notably leaner and denser than equivalent surplus on a testosterone-dominant cycle. In caloric deficit, Trenbolone's nutrient partitioning preserves lean tissue aggressively while fat oxidation proceeds — the classic cutting application. At maintenance, genuine recomposition (simultaneous lean mass gain and fat loss) is achievable, driven primarily by Trenbolone's nitrogen retention and nutrient partitioning. The compound is branded as "Cut Mix" because its anti-water, hardening, density-focused profile is most visually dramatic in a cutting context — but athletes use it successfully in lean bulk phases when they specifically want to avoid the water retention and estrogenic bulk that testosterone-heavy mass cycles produce.

The blend format offers operational advantages and one structural limitation. Operationally: a single vial replaces three vials; a single EOD injection of 1 ml delivers all three compounds co-drawn into one syringe, reducing needle events from three separate compound injections to one; and dosing is simplified — the 50/50/50 ratio is fixed and calibrated by total volume rather than three independent calculations. For athletes who want exactly the 1:1:1 ratio of the three compounds at the standard productive dose range (~350–525 mg/week total on EOD to twice-weekly scheduling), Ultrabol 150 is more convenient and typically more cost-effective than three separate vials. The structural limitation: the 1:1:1 ratio cannot be individually adjusted. An athlete who wants 400 mg/week Testosterone Propionate, 300 mg/week Drostanolone Propionate, and 200 mg/week Trenbolone Acetate — or any non-equal ratio — cannot achieve this from Ultrabol 150 alone without supplementing individual components. Athletes with specific ratio requirements or unusual dose preferences manage the three compounds independently; athletes whose preferred protocol aligns with the equal-ratio blend use Ultrabol 150 for the operational simplicity.

The detection window for any multi-compound blend is determined by the longest-detecting component, not an average. Testosterone Propionate and Drostanolone Propionate both clear within approximately 2–3 weeks of the final injection — their short Propionate esters and relatively straightforward metabolic pathways produce conventional detection windows. Trenbolone Acetate's metabolites, however, are detectable for approximately 5 months via modern IRMS analysis — a timeline that is independent of the Acetate ester's 1–2 day half-life. A tested athlete who discontinued Ultrabol 150 three weeks before competition would have fully cleared Testosterone Propionate and Drostanolone Propionate but would still be within Trenbolone Acetate's 5-month metabolite detection window. For any athlete subject to WADA-protocol anti-doping testing, the entire blend's detection window is effectively Trenbolone's 5-month metabolite window — the Propionate and Drostanolone components' shorter clearance is operationally irrelevant to competition eligibility.

Drostanolone's anti-estrogenic effect produces subtle signs distinct from AI-driven estrogen suppression. The positive indicators that Drostanolone is adequately managing estrogen alongside a modest testosterone dose include: absence of water retention in sub-cutaneous tissue (particularly around the mid-section, abdomen, and face — areas that typically fill with estrogenic water in testosterone-dominant cycles); stable body weight without rapid glycogen-driven scale fluctuations across injection timing; absence of nipple sensitivity or early gynecomastia signs; and normal joint function (sufficient estrogen for joint lubrication is maintained at adequately managed levels). Signs that additional AI is required despite Drostanolone co-administration: visible sub-cutaneous water retention disproportionate to caloric intake; nipple tenderness or sensitivity; blood pressure elevation consistent with estrogen-driven fluid retention; or bloodwork-confirmed estradiol elevation above the athlete's managed target range (typically 20–35 pg/ml during a performance cycle). The key distinction from AI over-suppression: joint pain (elbows, shoulders, knees), significantly reduced libido, mood depression, and cholesterol worsening indicate estrogen too low. Calibrating the AI requirement against bloodwork-confirmed estradiol while the Drostanolone is active is more accurate than relying on subjective symptoms alone.

Most users notice the first effects within the first one to two weeks of dosing.

The side profile depends on the compound class - the Side Effects section on the product page above covers the exact watchpoints for ultrabol.

Oral compounds clear within days of the last dose; injectable esters extend detection to weeks or months depending on the ester.

British Dragon Ultrabol 150 is available in this shop with international and domestic shipping.